Bullous pemphigoid, an immune-mediated condition characterized by large, fluid-filled blisters on the skin, is a rare but serious complication of cancer therapy with immune checkpoint inhibitors (ICIs ...

The FDA approved dupilumab (Dupixent) as the first targeted drug for bullous pemphigoid, a rare blistering skin disease that largely affects elderly patients, drugmakers Sanofi and Regeneron announced ...

Please provide your email address to receive an email when new articles are posted on . Nomacopan was well tolerated and beneficial in patients with bullous pemphigoid, according to phase 2a clinical ...

PV is characterized by the deposition of IgG antibodies against desmoglein 3 (Dsg3, a 130kDa protein) and desmoglein 1 (Dsg1) found in the mucous epithelium and in skin desmosomes, causing loss of ...

Clinical measurements of skin-related quality of life (SRQL) may aid in detecting critical disease severity information. Skin-related quality of life (SRQL) may be associated with flare-ups in ...

Trial met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placebo Dupixent is ...

BP can bear close resemblance to a variety of dermatoses including localized or generalized drug reactions, contact and allergic dermatitis, urticarial vasculitis, arthropod reactions, scabies, ...